Emerging drugs for hepatic encephalopathy

Bibliography

• Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification. Hepatology 2002;35:716-21
   PubMed Web of Science ®Google Scholar
• Amodio P, Montagnese S, Gatta A, et al. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004;19:253-67
   PubMed Web of Science ®Google Scholar
• Quero JC, Hartmann IJ, Meulstee J, et al. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology 1996;24:556-60
   PubMed Web of Science ®Google Scholar
• Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999;29:1662-7
   PubMed Web of Science ®Google Scholar
• Groeneweg M, Moerland W, Quero JC, et al. Screening of subclinical hepatic encephalopathy. J Hepatol 2000;32:748-53
   PubMed Web of Science ®Google Scholar
• Amodio P, Del Piccolo F, Petteno E, et al Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 2001;35:37-45
   PubMed Web of Science ®Google Scholar
• Ripoll C, Groszmann R, Garcia-Tsao G, et al. Gastroenterology 2007;133:481-8
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994;20:46-55
   PubMed Web of Science ®Google Scholar
• Rossle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994;330:165-71
   PubMed Web of Science ®Google Scholar
• Riggio O, Merli M, Pedretti G, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 1996;41:578-84
   PubMed Web of Science ®Google Scholar
• Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol 1993;88:514-9
   PubMed Web of Science ®Google Scholar
• Merkel C, Bolognesi M, Angeli P, et al. Prognostic indicators of survival in patients with cirrhosis and oesophageal varices, without previous bleeding. Am J Gastroenterol 1989;84:717-22
   PubMed Web of Science ®Google Scholar
• Christensen E, Krintel JJ, Hansen SM, et al. Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors. Scand J Gastroenterol 1989;24:999-1006
   PubMed Web of Science ®Google Scholar
• Del Olmo JA, Pena A., Serra MA, et al. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 2000;32:19-24
   PubMed Web of Science ®Google Scholar
• Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008;14:3609-15
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Saeian K, Hafeezullah M, et al. Patients with minimal hepatic encephalopathy have poor insight into their driving skills. Clin Gastroenterol Hepatol 2008;6:1135-9
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Hafeezullah M, Hoffmann RG, et al. Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology 2008;47:596-604
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Hafeezullah M, Hoffmann RG, et al. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007;102:1903-9
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar
• Klempnaue J. Review: surgical shunts and encephalopathy. Metab Brain Dis 2001;16:21-8
   PubMed Web of Science ®Google Scholar
• Somberg KA, Riegler JL, LaBerge JM, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995;90:549-55
   PubMed Web of Science ®Google Scholar
• Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005;42:1158-65
   PubMed Web of Science ®Google Scholar
• Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol 2008;103:2738-46
   PubMed Web of Science ®Google Scholar
• Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;7:639-43
   PubMed Web of Science ®Google Scholar
• Rolachon A, Zarski JP, Lutz JM, et al. Is the intestinal lavage with a solution of mannitol effective in the prevention of post-hemorrhagic hepatic encephalopathy in patients with liver cirrhosis? Results of a randomised prospective study. Gastroenterol Clin Biol 1994;18:1057-62
   PubMed Web of Science ®Google Scholar
• Riggio O, Nicolao F, Angeloni S, et al. Intractable hepatic encephalopathy after tips with polytetrafluoroethylene-covered stent-graft. Scand J Gastroenterol 2003;38:570-2
   PubMed Web of Science ®Google Scholar
• Uflacker R, d'Albuquerque LA, de Oliveira e Silva A, et al. Embolization to reverse severe recurrent hepatic encephalopathy. Arq Gastroenterol 1988;25:21-5
   PubMedGoogle Scholar
• Schliess F, Görg B, Häussinger D. RNA oxidation and zinc in hepatic encephalopathy and hyperammonemia. Metab Brain Dis 2009;24:119-34
   PubMed Web of Science ®Google Scholar
• Norenberg MD, Jayakumar AR, Rama Rao KV, et al. Metab Brain Dis 2007;22:219-34
   PubMed Web of Science ®Google Scholar
• Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008;57:1156-65
   PubMed Web of Science ®Google Scholar
• Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005;62:2295-304
   PubMed Web of Science ®Google Scholar
• Hassanein TI, Tofteng F, Brown RS, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46(6):1853-62
   PubMed Web of Science ®Google Scholar
• Ghanta RK, Mullen KD. Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical. Hepatology 2005;42:1206-7
   PubMedGoogle Scholar
• Merli M, Riggio O, Dally L, et al. Does malnutrition affect survival in cirrhosis? Hepatology 1996;23:1041-6
   PubMed Web of Science ®Google Scholar
• Rodríguez D, Martín A, Martinez-Valle F, et al. Prognosis after surviving to the first episode of hepatic encephalopathy [Abstract]. Hepatology 1998;28:268
   PubMed Web of Science ®Google Scholar
• Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000;95:2029-34
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001;96:2718-23
   PubMed Web of Science ®Google Scholar
• Blei AT, Cordoba J. Hepatic Encephalopathy. Am J Gastroenterol 2001;96:1968-76
   PubMed Web of Science ®Google Scholar
• Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomised controlled study. J Hepatol 2005;42:674-9
   PubMed Web of Science ®Google Scholar
• Heyman JK, Whitfield CJ, Brock KE, et al Dietary protein intakes in patients with hepatic encephalopathy and cirrhosis: current practice in NSW and ACT. Med J Aust 2006;185:542-3
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for treatment of MHE. Am J Gastroenterol 2008;103:11707-15
   Web of Science ®Google Scholar
• Kanematsu T, Koyanagi N, Matsumata T, et al. Lack of preventive effect of branched-chain amino acid solution on postoperative hepatic encephalopathy in patients with cirrhosis: a randomised, prospective trial. Surgery 1988;104:482-8
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Etemadian A, Hafeezullah M, et al. Testing for minimal hepatic encephalopathy in the United States: An AASLD Survey. Hepatology 2007;45:833-4
   PubMed Web of Science ®Google Scholar
• Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive function and health-related quality of life in cirrhotic patients with minimal hepatic encephalopathy. Hepatology 2007;45:549-59
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Hafeezullah M, Franco J, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008;135:1591-600
   PubMed Web of Science ®Google Scholar
• Mardini AH, Saxby BK, Record CO. Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant. Gastroenterology 2008;135(5):1582-90
   PubMed Web of Science ®Google Scholar
• Plauth M, Cabre E, Riggio O, et al. ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006;25:285-94
   PubMed Web of Science ®Google Scholar
• Barbaro G, Di Lorenzo G, Soldini M et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998;28:374-8
   PubMed Web of Science ®Google Scholar
• Sakurabajashi S, Sezai S, Yamamoto Y, et al. Embolization of portal-systemic shunts in cirrhotic patients with chronic–recurrent hepatic encephalopathy. Cardiovas Intervent Radiol 1997;20:120-4
   PubMed Web of Science ®Google Scholar
• Kato T, Uematsu T, Nishigaki Y, et al. Therapeutic effect of balloon-occluded retrograde transvenous obliteration on portal-systemic encephalopathy in patients with liver cirrhosis. Inter Med 2001;40:677-8
   PubMed Web of Science ®Google Scholar
• Uflacker R, Silva Ade O, D'Albuquerque LA, et al. Chronic portosystemic encephalopathy: embolisation of portosystemic shunts. Radiology 1987;165:721-5
   PubMed Web of Science ®Google Scholar
• Cordoba J, Olive G, Alonso J, et al. Improvement of magnetic resonance spectroscopic abnormalities but not pallidal hyperintensity followed amelioration of hepatic encephalopathy after occlusion of a large spleno-renal shunt. J Hepatol 2001;34:176-8
   PubMed Web of Science ®Google Scholar
• Sanyal A. Bass NM, Teperman L, et al. Chronic rifaximine for maintenance of remission of hepatic encephalopathy: subgroup analysis of a phase 3 trial [Abstract]. J Hepatol 2009;50:222
   PubMedGoogle Scholar
• Als-Nielsen B, Gluud LL, Gluud C, et al. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046-52
   PubMed Web of Science ®Google Scholar
• Morgan MY, Blei A, Grüngreiff K, et al. The treatment of hepatic encephalopathy. Metab Brain Dis 2007;22:389-405
   PubMed Web of Science ®Google Scholar
• Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet 2005;365:431-3
   PubMed Web of Science ®Google Scholar
• Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997;25:1351-60
   PubMed Web of Science ®Google Scholar
• Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998;28:856-64
   PubMed Web of Science ®Google Scholar
• Ahmad I, Khan AA, Alam A, et al. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. J Coll Physicians Surg Pak 2008;18:684-7
   PubMed Web of Science ®Google Scholar
• Poo JL, Góngora J, Sánchez-Avila F, et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 2006;5:281-8
   PubMedGoogle Scholar
• Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomised trial. Hepatology 1992;16:138-44
   PubMed Web of Science ®Google Scholar
• Efrati C, Masini A, Merli M, et al. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol 2000;95:3574-8
   PubMed Web of Science ®Google Scholar
• Riggio O, Merli M, Capocaccia L, et al. Zinc supplementation reduces blood ammonia and increase liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992;16:785-9
   PubMed Web of Science ®Google Scholar
• Reding P, Duchateau J, Battaille C, et al. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984;2:493-5
   PubMed Web of Science ®Google Scholar
• Riggio O, Ariosto F, Merli M, et al. Short term oral zinc supplementation does not improve chronic hepatic encephalopathy. Dig Dis Sci 1991;36:1204-8
   PubMed Web of Science ®Google Scholar
• Goulenok C, Bernard B, Cadranel JF, et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2002;16(3):361-72
   PubMed Web of Science ®Google Scholar
• Als-Nielsen B, Kjaergard LL, Gluud C, et al. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001;4:CD00279
   Google Scholar
• Naylor CD, O'Rourke K, Detsky AS, et al. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta analysis. Gastroenterology 1989;97:1033-42
   PubMed Web of Science ®Google Scholar
• Als-Nielsen B, Koretz RL, Kjaergard L, et al Branched-chain amino acids for hepatic encephalopathy. The Cochrane Library, John Wiley and Sons Chichester, UK, Issue 2;2004
   Google Scholar
• Malaguarnera M, Pistone G, Astuto M, et al. Effects of L-Acetylcarnitine on cirrhotic patients with hepatic coma: randomized double blind, placebo controlled trial. Dig Dis Sci 2006;51:2242-7
   PubMed Web of Science ®Google Scholar
• Loguercio C, Abbiati R, Rinaldi M, et al. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995;23:39-46
   PubMed Web of Science ®Google Scholar
• Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-9
   PubMed Web of Science ®Google Scholar
• Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005;3:184-91
   PubMed Web of Science ®Google Scholar
• Hiraishi M, Takahama T, Yamazaki Z, et al. Int J Artif Organs 1989;12:114-20
   PubMed Web of Science ®Google Scholar
• Hiraishi M. The effect of oral adsorbent on surgically induced hepatic failure. Jpn J Surg 1987;17:517-27
   PubMedGoogle Scholar
• Nicaise C, Prozzi D, Viaene E, et al. Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents. Hepatology 2008;48:1184-92
   PubMed Web of Science ®Google Scholar
• Carpenedo R, Mannaioni G, Moroni F, et al. Oxindole, a neurodepressant tryptophan metabolite, accumulates in blood or brain of rats with hepatic failure. J Neurochem 1998;70:1998-2003
   PubMed Web of Science ®Google Scholar
• Carpenedo R, Carlà, Moneti G, et al. Identification and measurement of oxindole (2-Indolinone) in the mammalian brain and other rat organs. Analyt Biochem 1997;244:74-9
   PubMed Web of Science ®Google Scholar
• Ridola L, Angeloni S, Mannaioni G, et al. Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: relationship to hepatic encephalopathy [Abstract]. Hepatology 2008;48;S4
   PubMed Web of Science ®Google Scholar
• Olde Damink SWM, Jalan R, Dejong CHC, et al. Interorgan ammonia trafficking in liver disease. Met Brain Dis 2008;24:169-81
   PubMed Web of Science ®Google Scholar
• Jalan R, Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut 2003;52:1041-5
   PubMed Web of Science ®Google Scholar
• Jalan R, Wright G, Davies NA, et al. L-ornithine phenylacetate: a novel treatment for hyperammoniemia and hepatic encephalopathy. Med Hypotheses 2007;69:1064-9
   PubMed Web of Science ®Google Scholar
• Wright G, Davies NA, Ytrebo LM, et al. L-Onithyne phenilacetate reduces arterial ammonia, improves brain osmolytes and reuces brain water in a bile duct ligated rat model of cirrhosis [Abstract]. Hepatology 2007
   Google Scholar
• Enns GM, Berry SA, Berry GT, et al. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007;356:2282-92
   PubMed Web of Science ®Google Scholar
• Dragon Y, Avraham Y. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP activated kinase. FASEB J 2007;10:2431-41
   Web of Science ®Google Scholar
• Erceg S, Monfort P, et al. Oral administration of sildenafil restore learning ability in rats with hyperammoniemia and with portacaval shunts. Hepatology 2005;41:299-306
   PubMed Web of Science ®Google Scholar
• Canales JJ, Elayadi A, Errami A, et al. Chronic hyperammonemia alters motor and neurochemicals responses to activtion of group I metabotropic glutamate receptors in the nucleus accumbens in rats in vivo. Neurobiol Dis 14:380-90
   PubMed Web of Science ®Google Scholar
• Shawcross DL, Davies NA, Williams R, et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247-54
   PubMed Web of Science ®Google Scholar
• Chung C, Gottstein J, Blei AT, et al. Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portacaval anastomosis. Hepatology 2001;34:249-54
   PubMed Web of Science ®Google Scholar
• Ahboucha S, Jiang W, Chatauret N, et al. Indomethacin improves locomotor deficit and reduces brain concentrations of neuroinhibitory steroids in rats following portacaval anastomosis. Neurogastroenterol Motil 2008;2:949-57
   Web of Science ®Google Scholar
• Cauli O, Rodrigo R, Piedrafita B, et al. Hepatology 2007;46:514-9
   PubMed Web of Science ®Google Scholar
• Cordoba J, Gottstein J, Blai AT. Chronic hyponatremia exacerbated ammonia induced brain edema in rats after porta-caval anastomosis. J Hepatol 1998;29:589-94
   PubMed Web of Science ®Google Scholar
• Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance and management. Hepatology 2008;48:1002-10
   PubMed Web of Science ®Google Scholar